Key result
A solid-phase extraction method successfully measured free doxorubicin in rat plasma, which ranged from 5.35% to 14.09% of total doxorubicin after liposomal doxorubicin administration.
Provides a novel analytical tool for pharmacokinetic monitoring; leaves open whether this method can be translated to.
Background: Measuring free drug concentration following systemic administration of a liposomal drug is a crucial aspect of the assessment of its in vivo behavior. Therefore we require an efficient method to separate free drug in the plasma from encapsulated drug. Objectives: To study the pharmacokinetics of free doxorubicin (DOX) released from liposomal doxorubicin (L-DOX) in rats. Methods: L-DOX was prepared with encapsulation efficiency of 90% and was injected intravenously into rats. A solid-phase extraction (SPE) method coupled with UPLC–MS/MS was used to measure the concentration of F-DOX in rat plasma without disrupting the integrity of L-DOX. Results: This method exhibited a linear range of F-DOX from 0.2 to 200 ng/mL. Recovery, precision, linearity and accuracy of this technique appear satisfactory for pharmacokinetic study. The constituents of F-DOX ranged from 5.35% to 14.09% of total DOX in plasma at each time point measured after L-DOX administration. Conclusion: SPE method was suitable for studying the pharmacokinetics of F-DOX in rats receiving L-DOX.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) studied this question. Liposomal doxorubicin (L-DOX) was evaluated on Pharmacokinetics of free doxorubicin (F-DOX) released from L-DOX. A solid-phase extraction method successfully measured free doxorubicin in rat plasma, which ranged from 5.35% to 14.09% of total doxorubicin after liposomal doxorubicin administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: